Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Are ACE inhibitors acceptable ingredients in polypills?

The Lancet suggested in their Editorial (March 11, p 984)1 that an affordable polypill would be welcomed in the more than 30 million people worldwide who do not have access to appropriate secondary prevention. When considering such numbers, balance between benefits and harms becomes exceedingly important. As can be estimated by the number needed to treat, most people taking a polypill for years or decades will never be benefited by it. They nevertheless have to put up with adverse events, which are up to 16% higher (risk ratio 1·16, 95% CI 1·09–1·25) in participants randomly assigned polypills than in those assigned usual care.